Clinical trial · Interventional
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
NCT05381077CI-TRIAL-00058600MM-ZTEunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the added value of magnetic resonance imaging (MRI) of the skeleton compared to other validated techniques for the detection of bone lesions in patients with multiple myeloma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Whole body MRI
- description
- There is only one cohort where each patient have the standard of care follow up (PET/CT) and Whole body MRI- ZTE sequence for the study
- interventionNames
- Other: MRI
Primary outcomes (2)
- measure
- Evaluation of the diagnostic performance of the different imaging protocols
- timeFrame
- through study completion, an average of 1 year
- description
- The diagnostic performance of the different imaging protocols will be evaluated by analyzing the receptor efficiency function (ROC curve) and by estimating the Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value (NPV) ) as well as the Predictive Accuracy (Acc) of the different imaging protocols.
- measure
- Comparison of Sensitivity (Se) and Predictive Precision (Acc) of the different imaging protocols
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging. * Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.). * Patient requiring a PET / CT considered as the technique of choice in these stages of the disease. Exclusion Criteria: * Implanted material incompatible with MRI. * Severe claustrophobia. * Pregnant women
References
Publications (3)
- DERIVEDLepot D, Chabot C, Duchene G, Mandava S, Fung M, Poujol J, Vekemans MC, Triqueneaux P, Watte N, Gheysens O, Michoux N, Lecouvet FE. Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions. Eur Radiol Exp. 2026 Jun 5;10(1):81. doi: 10.1186/s41747-026-00734-x. PMID 42247107
- DERIVEDChabot C, Haegeman M, Chaouch E, Dumitriu D, Menten R, Steenhaut P, Bernard P, Triqueneaux P, Michoux N, Lecouvet FE. MRI-based pseudo-CT sequences as a radiation-free alternative to CT for obstetric pelvimetry: a proof-of-concept study. Eur Radiol Exp. 2025 May 19;9(1):52. doi: 10.1186/s41747-025-00585-y. PMID 40388042
- DERIVEDLecouvet FE, Zan D, Lepot D, Chabot C, Vekemans MC, Duchene G, Chiabai O, Triqueneaux P, Kirchgesner T, Taihi L, Poujol J, Gheysens O, Michoux N. MRI-based Zero Echo Time and Black Bone Pseudo-CT Compared with Whole-Body CT to Detect Osteolytic Lesions in Multiple Myeloma. Radiology. 2024 Oct;313(1):e231817. doi: 10.1148/radiol.231817. PMID 39377681